<DOC>
	<DOCNO>NCT03058029</DOCNO>
	<brief_summary>This study asses effect Gelesis200 body weight overweight obese subject prediabetes metformin-treated type 2 diabetes .</brief_summary>
	<brief_title>Effect Gelesis200 Body Weight Overweight Obese Subjects With Prediabetes Metformin-treated Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>Body Mass Index ( BMI ) ≥27 ≤40 kilogram ( kg ) /meter ( M ) 2 body weight &lt; 120 kg Prediabetic subject FPG ≥100 milligram ( mg ) /deciliter ( dL ) &lt; 126 mg/dL [ ≥5.6 millimole ( mmol ) /liter ( L ) &lt; 7.0 mmol/L ] Screening Visits HbA1c ≤6.4 % [ 1 value within range , value ≥126 mg/dL ( ≥7.0 mmol/L ) HbA1c ≥5.7 % ≤6.4 % ] metformintreated diabetic subject FPG ≥70 mg/dL ≤270 mg/dL ( ≥3.9 mmol/L ≤15.1 mmol/L ) Screening Visits . Fasting serum insulin &lt; 20 microunit ( mU ) /milliliter ( mL ) Screening Visits prediabetic subject . Ability follow verbal write instruction Consent obtain via sign ICF Pregnancy [ positive serum urine pregnancy test ( ) females childbearing potential ] Absence medically approve contraception female childbearing potential [ exempli gratia ( e.g . ) , hysterectomy , oral contraceptive medication , intrauterine device combine barrier method , two ( 2 ) combine barrier method diaphragm condom spermicide , condom spermicide ; bilateral tubal ligation vasectomy acceptable contraceptive method combine another single method ] History allergic reaction carboxymethylcellulose ( CMC ) , citric acid , maltodextrin , gelatin , titanium dioxide Participation weight loss study within past twelve ( 12 ) month Administration Gelesis100 Gelesis200 previous study Administration investigational product within one ( 1 ) month prior Screening Visit Smoking cessation within six ( 6 ) month prior Screening Visit consider smoke cessation study Anticipated surgical intervention study period Known Type 1 Diabetes History eat disorder include binge eating ( except mild binge eat ) emesis ≥2/week cause Weight change &gt; 3 % within three ( 3 ) month prior Screening period Supine systolic blood pressure ( SBP ) &gt; 160 millimeter mercury ( mmHg ) and/or supine diastolic blood pressure ( DBP ) &gt; 95 mmHg Angina , coronary bypass , myocardial infarction within six ( 6 ) month prior Screening Visit History swallow disorder Esophageal anatomic abnormality ( e.g. , web , diverticuli , ring ) History gastroesophageal reflux disease History gastric duodenal ulcer History gastroparesis ( e.g. , chronic nausea , vomit ≥2 occurrence per week , heartburn , etc . ) History gastric bypass gastric surgery History small bowel resection ( except relate appendectomy ) History intestinal stricture ( e.g. , Crohn 's disease ) History intestinal obstruction high risk intestinal obstruction , include suspect small bowel adhesion History abdominal radiation treatment History pancreatitis within past 12 month History malabsorption Laxative user , except stable dos within one ( 1 ) month prior Screening Visit History hepatitis B C History human immunodeficiency virus ( HIV ) History cancer within past five ( 5 ) year ( except adequatelytreated localized basal cell skin cancer situ uterine cervical cancer ) Any clinically significant disease interfere assessment Gelesis200 ( e.g. , disease require corrective treatment , potentially lead study discontinuation ) Abnormal serum thyroidstimulating hormone ( TSH ) HbA1c &gt; 8.5 % ( &gt; 69 mmol/mole ( mol ) ) Serum lowdensity lipoprotein ( LDL ) cholesterol ≥160 mg/dL ( ≥4.15 mmol/L ) Serum triglycerides ≥350 mg/dL ( ≥3.96 mmol/L ) Positive test drug abuse urine Any relevant biochemical abnormality interfere assessment Gelesis200 Antiobesity medication ( include herbal preparation ) within one ( 1 ) month prior Screening Visit Systemic corticosteroid within one ( 1 ) month prior Screening Visit Thyroid hormone preparation within one ( 1 ) month prior Screening Visit [ except stable dose replacement therapy least two ( 2 ) month ] TSH suppression therapy thyroid cancer Estrogen within one ( 1 ) month prior Screening Visit [ except stable dose replacement therapy contraceptives least one ( 1 ) month ] Any medication know cause weight loss weight gain within one ( 1 ) month prior Screening Visit Antidiabetic medication within one ( 1 ) month prior Screening Visit [ except stable dos metformin least one ( 1 ) month subject Type 2 Diabetes ] Change medication treat hypertension within one ( 1 ) month prior Screening Visit Change medication treat dyslipidemia within one ( 1 ) month prior Screening Visit Anticipated requirement use prohibit concomitant medication Any condition , opinion Investigator Sponsor , would interfere subject 's ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>